Cormorant Asset Management, LP - Q1 2016 holdings

Add to watchlist

$664 Million is the total value of Cormorant Asset Management, LP's 84 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 35.7% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
ALDR BuyALDER BIOPHARMACEUTICALS INC$36,673,000
+46.6%
1,497,475
+97.7%
5.52%
+84.6%
HRTX BuyHERON THERAPEUTICS INC$33,233,000
-26.2%
1,750,000
+3.8%
5.01%
-7.0%
SAGE BuySAGE THERAPEUTICS INC$30,297,000
+65.0%
945,000
+200.0%
4.56%
+107.7%
NKTR BuyNEKTAR THERAPEUTICS$27,500,000
+113.3%
2,000,000
+161.4%
4.14%
+168.7%
NVRO BuyNEVRO CORP$27,308,000
+52.4%
485,386
+82.9%
4.11%
+92.0%
EGRX BuyEAGLE PHARMACEUTICALS INC$20,250,000
-42.9%
500,000
+25.0%
3.05%
-28.1%
DVAX BuyDYNAVAX TECHNOLOGIES CORP$18,759,000
+35.0%
975,000
+69.6%
2.83%
+70.0%
PTI NewPROTEOSTASIS THERAPEUTICS IN$16,644,000–1,726,599
+100.0%
2.51%–
PTLA BuyPORTOLA PHARMACEUTICALS INC$14,280,000
-44.5%
700,000
+40.0%
2.15%
-30.1%
MGNX BuyMACROGENICS INC$13,125,000
-15.2%
700,000
+40.0%
1.98%
+6.7%
VTAE BuyVITAE PHARMACEUTICALS INC$11,503,000
+1.9%
1,735,000
+178.3%
1.73%
+28.4%
NERV BuyMINERVA NEUROSCIENCES INC$10,763,000
+54.9%
1,752,946
+53.1%
1.62%
+95.1%
CELG NewCELGENE CORP$10,009,000–100,000
+100.0%
1.51%–
CPXX NewCELATOR PHARMACEUTICALS INC$6,839,000–620,000
+100.0%
1.03%–
ZYNE BuyZYNERBA PHARMACEUTICALS INC$4,489,000
+25.0%
475,035
+33.2%
0.68%
+57.2%
AGRX BuyAGILE THERAPEUTICS INC$3,459,000
+94.7%
557,053
+206.0%
0.52%
+144.6%
SNDX NewSYNDAX PHARMACEUTICALS INC.$2,856,000–214,419
+100.0%
0.43%–
CFRX BuyCONTRAFECT CORP$2,837,000
+154.9%
834,406
+256.0%
0.43%
+221.1%
CLRB NewCELLECTAR BIOSCIENCES INC$180,000–52,999
+100.0%
0.03%–
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2016-05-17
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
QUOTIENT LTD30Q3 20214.3%
ASCENDIS PHARMA A/S30Q4 20224.8%
MINERVA NEUROSCIENCES INC29Q3 20214.4%
ACCELERON PHARMA INC28Q2 20213.4%
OMEROS CORP27Q3 20216.5%
MIRATI THERAPEUTICS INC25Q4 20227.6%
BLUEPRINT MEDICINES CORP25Q3 20213.6%
APELLIS PHARMACEUTICALS INC24Q3 20238.6%
NEUROCRINE BIOSCIENCES INC24Q1 20204.6%
ROCKET PHARMACEUTICALS, INC23Q3 20232.4%

View Cormorant Asset Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Cormorant Asset Management, LP Q1 2016 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Ambrx Biopharma Inc.March 13, 202342,771,365-
Altimmune, Inc.February 14, 20232,600,000-
Arcellx, Inc.February 14, 20232,075,000-
BioAtla, Inc.February 14, 20232,499,250-
Eledon Pharmaceuticals, Inc.February 14, 20231,391,663-
GreenLight Biosciences Holdings, PBCFebruary 14, 20234,751,020-
Prometheus Biosciences, Inc.February 14, 2023700,000-
Tango Therapeutics, Inc.February 14, 20231,000,000-
VectivBio Holding AGFebruary 14, 20231,515,087-
Viridian Therapeutics, Inc.\DEFebruary 14, 20231,100,000-

View Cormorant Asset Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
SC 13G2024-05-13
42024-05-08
SC 13G2024-04-29
42024-04-22
SC 13G/A2024-04-15
42024-04-03
SC 13G2024-03-21
42024-03-18
SC 13G/A2024-03-18

View Cormorant Asset Management, LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (663826000.0 != 663828000.0)
  • The reported has been restated
  • The reported has been amended

Export Cormorant Asset Management, LP's holdings

CSVXLS